Acetylcysteine (N-Acetylcysteine / NAC) vs Acebrophylline

1. Drug Identity

2. Mechanism of Action

• Cleaves disulfide bonds in mucus glycoproteins, directly reducing mucus viscosity and gel structure
• Donates cysteine for glutathione synthesis, making it a powerful antioxidant
• Protects against oxidative stress, which is especially relevant in COPD where cigarette smoke depletes glutathione
• Additional mechanism: replenishes glutathione stores to protect hepatocytes in paracetamol overdose

• Ambroxol component:
  • Stimulates synthesis and secretion of pulmonary surfactant (type II pneumocytes), liquefying the sol phase of mucus
  • Increases ciliary motility, enhancing mucociliary clearance
  • Reduces gel-phase viscosity without directly cleaving bonds
  • Anti-inflammatory: reduces TNF-alpha and leukotriene release
• Theophylline-7-acetate component:
  • Inhibits phosphodiesterase (PDE), raising intracellular cAMP
  • Causes bronchial smooth muscle relaxation (bronchodilation)
  • Selectively inhibits phosphatidylcholine and phospholipase A
  • Anti-inflammatory at low doses (histone deacetylase activation)
• Net effect: Acebrophylline shows 45% improvement in lung health vs ambroxol alone, due to synergism of its two components

3. Pharmacological Actions Summary

4. Indications

• COPD - reducing exacerbation frequency (especially at 600 mg twice daily; supported by PANTHEON trial in moderate-severe COPD)
• Chronic bronchitis / viscous secretions in cystic fibrosis
• Paracetamol (acetaminophen) overdose - hepatoprotective (IV form)
• Contrast-induced nephropathy prevention (IV/oral)
• Nebulized form for thinning airway secretions in ICU / post-op
• Vernal keratoconjunctivitis (topical - dissolves mucus filaments)

• COPD (add-on therapy, especially when bronchospasm co-exists with hypersecretion)
• Bronchial asthma (particularly when inhaler therapy is not preferred or as add-on to ICS/LABA)
• Acute/chronic bronchitis with both secretion problems and airway obstruction
• Preferred in patients needing simultaneous mucolysis and bronchodilation in a single oral tablet

5. Clinical Evidence

• The PANTHEON study established NAC (600 mg BD) as useful in moderate-severe COPD, significantly reducing exacerbation rates
• Fishman's Pulmonary Diseases notes that NAC "does not alter the decline in FEV1" but "may have a role in reducing exacerbations" - Murray & Nadel's confirms a "small reduction in number of exacerbations" with "small improvement in cough, decrease in volume of sputum"

• The CARE study (2025) - a prospective post-marketing surveillance study of the NAC + Acebrophylline combination ("Abiways") in 97 patients with moderate-severe COPD and asthma - showed FEV1 improved from 1.287L to 1.484L (p<0.001), and COPD CAT scores improved from 17.2 to 10.6 (p=0.0001). No severe adverse events were reported. (PMID 40454226)
• A separate study (PMC4225926) comparing acebrophylline vs sustained-release theophylline in COPD found acebrophylline better tolerated with equivalent or superior bronchodilatory and mucociliary effects

6. Dosing

7. Adverse Effects

• Oral: nausea, vomiting, stomatitis, bad odor
• IV: anaphylactoid reactions (flushing, bronchospasm, hypotension) - more common with rapid infusion
• Inhaled: bronchospasm (especially in asthmatics - always give with bronchodilator)

• Generally well tolerated (better tolerated than theophylline alone due to lower theophylline dose)
• Nausea, headache, palpitations (theophylline-related)
• Theophylline-related toxicity at high doses (narrow therapeutic index concern, though acebrophylline uses the acetate form which is considered safer)

8. Key Differentiating Points

1. NAC is the only one with non-respiratory indications - it is a life-saving antidote for paracetamol overdose and a renal protectant for contrast nephropathy
2. Acebrophylline adds bronchodilation - NAC has no bronchodilatory effect; acebrophylline is preferred when airway obstruction co-exists with mucus hypersecretion
3. NAC is the stronger antioxidant - important in COPD pathogenesis driven by oxidative stress
4. Acebrophylline stimulates surfactant - useful in conditions where alveolar stability is impaired
5. Both can be combined - the CARE study (2025) shows NAC + Acebrophylline together improve both QoL and FEV1 in COPD and asthma, suggesting complementary (not redundant) mechanisms
6. NAC has inhaled/IV forms; acebrophylline is oral only

• Murray & Nadel's Textbook of Respiratory Medicine, Expectorants and Mucolytics section
• Fishman's Pulmonary Diseases and Disorders, Chronic Maintenance Therapy section
• K.J. Lee's Essential Otolaryngology, Mucolytics and Expectorants section
• Dhar R et al., CARE Study, J Asthma Allergy 2025 (PMID 40454226)

The Rumack-Matthew Protocol (Nomogram)

Background

Why Paracetamol is Hepatotoxic in Overdose

• Glucuronidation and sulfation pathways become saturated
• A much larger fraction is shunted to CYP450 → massive NAPQI production
• When hepatic glutathione stores fall below 30% of normal, NAPQI binds covalently to hepatic macromolecules
• This causes centrilobular hepatic necrosis

How the Nomogram Works

• Y-axis: Serum paracetamol concentration (µg/mL) - on a log scale
• X-axis: Time after ingestion (hours, from 4 to 24 hours) - linear scale

1. Probable hepatic toxicity
2. Possible hepatic toxicity
3. No hepatic toxicity

Rules for Using the Nomogram

• Single acute oral ingestion
• Ingestion time is accurately known
• Sample drawn between 4 and 24 hours after ingestion

• Chronic or repeated supratherapeutic ingestion
• Staggered ingestion over several hours
• Extended-release paracetamol formulations
• Levels drawn before 4 hours (no prognostic value)
• Levels drawn after 24 hours

For patients with uncertain timing, staggered, or chronic ingestion - treat empirically with NAC

Four Clinical Stages of Toxicity (Tintinalli's)

Treatment: N-Acetylcysteine (NAC)

IV NAC Protocol (21-hour regimen - standard US protocol):

Oral NAC Protocol (72-hour regimen):

• Loading dose: 140 mg/kg
• Maintenance: 70 mg/kg every 4 hours for 17 further doses
• Used when IV route not available, or in patients at high risk for anaphylactoid reactions (e.g., asthmatics)

King's College Criteria (for Transplant Evaluation)

• pH < 7.3 (after resuscitation)
• OR all three of: PT >100 sec + creatinine >300 µmol/L + Grade III-IV encephalopathy

Limitations of the Nomogram

1. Only valid for acute single ingestion - not chronic use
2. Requires accurate time of ingestion
3. Not valid for levels drawn before 4 hours
4. Does not account for enzyme inducers (e.g., chronic alcohol, rifampicin, anticonvulsants) which increase CYP2E1 activity and NAPQI generation - these patients may have toxicity at lower plasma levels
5. Extended-release formulations may have delayed peaks; a second level at 4-6 hours later is recommended if the first plots below the line